{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:13:35Z","timestamp":1789456415200,"version":"build-2803163510"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00228-026-04181-w","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:56:47Z","timestamp":1789005407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clobazam in pediatric drug-resistant epilepsy: from pharmacology to clinical practice"],"prefix":"10.1007","volume":"82","author":[{"given":"Jun","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minling","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianling","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"4181_CR1","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/epi.17241","volume":"63","author":"N Specchio","year":"2022","unstructured":"Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P et al (2022) International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions. Epilepsia 63:1398\u20131442. https:\/\/doi.org\/10.1111\/epi.17241","journal-title":"Epilepsia"},{"key":"4181_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/epi.18238","volume":"66","author":"T Vikin","year":"2025","unstructured":"Vikin T, Lossius MI, Brandlistuen RE, Chin RF, Aaberg KM (2025) Incidence of childhood and youth epilepsy: a population-based prospective cohort study utilizing current International League Against Epilepsy classifications for seizures, syndromes, and etiologies. Epilepsia 66:776\u2013789. https:\/\/doi.org\/10.1111\/epi.18238","journal-title":"Epilepsia"},{"key":"4181_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1684\/epd.2015.0736","volume":"17","author":"P Camfield","year":"2015","unstructured":"Camfield P, Camfield C (2015) Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord 17:117\u2013123. https:\/\/doi.org\/10.1684\/epd.2015.0736","journal-title":"Epileptic Disord"},{"key":"4181_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/archdischild-2018-316035","volume":"104","author":"P Harijan","year":"2019","unstructured":"Harijan P, Seal AK, Prasad M, Whitehouse WP (2019) Fifteen-minute consultation: when medicines don\u2019t work\u2014the child with poorly controlled seizures. Arch Dis Child Educ Pract Ed 104:135\u2013140. https:\/\/doi.org\/10.1136\/archdischild-2018-316035","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"4181_CR5","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.2147\/JMDH.S493116","volume":"17","author":"JH Saing","year":"2024","unstructured":"Saing JH, Sari DK, Supriatmo, Fitri A, Pratama MA (2024) Impact of vitamin D and IL-1\u03b2 on quality of life in pediatric drug-resistant epilepsy. J Multidiscip Healthc 17:5571\u20135581. https:\/\/doi.org\/10.2147\/JMDH.S493116","journal-title":"J Multidiscip Healthc"},{"key":"4181_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S1474-4422(15)00250-1","volume":"15","author":"A McTague","year":"2016","unstructured":"McTague A, Howell KB, Cross JH, Kurian MA, Scheffer IE (2016) The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol 15:304\u2013316. https:\/\/doi.org\/10.1016\/S1474-4422(15)00250-1","journal-title":"Lancet Neurol"},{"key":"4181_CR7","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/brain\/awab162","volume":"144","author":"JD Symonds","year":"2021","unstructured":"Symonds JD, Elliott KS, Shetty J, Armstrong M, Brunklaus A, Cutcutache I et al (2021) Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain 144:2879\u20132891. https:\/\/doi.org\/10.1093\/brain\/awab162","journal-title":"Brain"},{"key":"4181_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/cns.12399","volume":"21","author":"AC Gauthier","year":"2015","unstructured":"Gauthier AC, Mattson RH (2015) Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy. CNS Neurosci Ther 21:543\u2013548. https:\/\/doi.org\/10.1111\/cns.12399","journal-title":"CNS Neurosci Ther"},{"key":"4181_CR9","volume-title":"Clobazam (Onfi) prescribing information","author":"FDA","year":"2011","unstructured":"FDA (2011) Clobazam (Onfi) prescribing information. Food and Drug Administration, Silver Spring"},{"key":"4181_CR10","doi-asserted-by":"publisher","first-page":"6516","DOI":"10.4081\/pr.2016.6516","volume":"8","author":"M Pernea","year":"2016","unstructured":"Pernea M, Sutcliffe AG (2016) Clobazam and its use in epilepsy. Pediatr Rep 8:6516. https:\/\/doi.org\/10.4081\/pr.2016.6516","journal-title":"Pediatr Rep"},{"key":"4181_CR11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.12290\/xhyxzz.2022-0421","volume":"13","author":"B Zhang","year":"2022","unstructured":"Zhang B, Zhang SY, Xu TT, Liu X, Sun Z, Tian X et al (2022) Expert consensus on clobazam in the treatment of refractory epilepsy (2022). Med J Peking Union Med Coll Hosp 13:768\u2013782. https:\/\/doi.org\/10.12290\/xhyxzz.2022-0421","journal-title":"Med J Peking Union Med Coll Hosp"},{"key":"4181_CR12","doi-asserted-by":"publisher","first-page":"1757055","DOI":"10.3389\/fneur.2026.1757055","volume":"17","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Liu X, Su Z, Xu X, She Y, Chen S et al (2026) Efficacy and safety of adjunctive clobazam in Chinese patients with drug-resistant epilepsy: a single-center real-world study. Front Neurol 17:1757055. https:\/\/doi.org\/10.3389\/fneur.2026.1757055","journal-title":"Front Neurol"},{"key":"4181_CR13","doi-asserted-by":"publisher","first-page":"e70403","DOI":"10.1002\/bmc.70403","volume":"40","author":"T Zhao","year":"2026","unstructured":"Zhao T, Zhang HL, Yu J, Feng J, Li HJ, Sun Y et al (2026) Therapeutic drug monitoring of clobazam, perampanel, and lacosamide using a UPLC-MS\/MS method: analysis of 5-year experience in a large cohort of pediatric epilepsy patients from China. Biomed Chromatogr 40:e70403. https:\/\/doi.org\/10.1002\/bmc.70403","journal-title":"Biomed Chromatogr"},{"key":"4181_CR14","doi-asserted-by":"publisher","first-page":"CD004154","DOI":"10.1002\/14651858.CD004154.pub5","volume":"10","author":"R Bresnahan","year":"2019","unstructured":"Bresnahan R, Martin-McGill KJ, Williamson J, Michael BD, Marson AG (2019) Clobazam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev 10:CD004154. https:\/\/doi.org\/10.1002\/14651858.CD004154.pub5","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"4181_CR15","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/epi4.70261","volume":"11","author":"I Ciullo","year":"2026","unstructured":"Ciullo I, D\u2019Aniello A, Panzini C, Salamone EM, Quarato PP, Grammaldo LG et al (2026) Effectiveness of adjunctive low-dose clobazam in adults with focal drug-resistant epilepsy and incomplete response to cenobamate: a real-world study. Epilepsia Open 11(3):962\u2013972. https:\/\/doi.org\/10.1002\/epi4.70261","journal-title":"Epilepsia Open"},{"issue":"1","key":"4181_CR16","doi-asserted-by":"publisher","first-page":"e101154","DOI":"10.7759\/cureus.101154","volume":"18","author":"B Fang","year":"2026","unstructured":"Fang B, Haroon M, Kalantzis E, Kurukumbi M (2026) Clobazam in adult drug-resistant epilepsy: excellent long-term retention and potential synergy with neuromodulation. Cureus 18(1):e101154. https:\/\/doi.org\/10.7759\/cureus.101154","journal-title":"Cureus"},{"issue":"5","key":"4181_CR17","doi-asserted-by":"publisher","first-page":"e669","DOI":"10.1212\/CPJ.0000000000000992","volume":"11","author":"A Jamil","year":"2021","unstructured":"Jamil A, Levinson N, Gelfand M, Hill CE, Khankhanian P, Davis KA et al (2021) Efficacy and tolerability of clobazam in adults with drug-refractory epilepsy. Neurol Clin Pract 11(5):e669\u2013e676. https:\/\/doi.org\/10.1212\/CPJ.0000000000000992","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"4181_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","volume":"4","author":"C Baethge","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S (2019) SANRA\u2014a scale for the quality assessment of narrative review articles. Res Integr Peer Rev 4(1):5. https:\/\/doi.org\/10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"4181_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","volume":"26","author":"R Sankar","year":"2012","unstructured":"Sankar R (2012) GABAA receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs 26:229\u2013244. https:\/\/doi.org\/10.2165\/11599020-000000000-00000","journal-title":"CNS Drugs"},{"key":"4181_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-0045-1811235","volume":"83","author":"LF Pinto","year":"2025","unstructured":"Pinto LF, Mendon\u00e7a GS, Guerreiro CAM (2025) Which are the options and dosages for clobazam shortages on epilepsy treatment? review of literature and survey of specialists. Arq Neuropsiquiatr 83:57\u201362. https:\/\/doi.org\/10.1055\/s-0045-1811235","journal-title":"Arq Neuropsiquiatr"},{"key":"4181_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41586-022-04517-3","volume":"604","author":"A Sente","year":"2022","unstructured":"Sente A, Desai R, Naydenova K, Malinauskas T, Jounaidi Y, Miehling J et al (2022) Differential assembly diversifies GABAA receptor structures and signalling. Nature 604:190\u2013194. https:\/\/doi.org\/10.1038\/s41586-022-04517-3","journal-title":"Nature"},{"key":"4181_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuropharm.2011.08.040","volume":"62","author":"H M\u00f6hler","year":"2012","unstructured":"M\u00f6hler H (2012) The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 62:42\u201353. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.08.040","journal-title":"Neuropharmacology"},{"key":"4181_CR23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P02.101","volume":"78","author":"AA Jensen","year":"2012","unstructured":"Jensen AA, Hammer H, Ebert B, Jensen HS (2012) Clobazam and its active metabolite, N-desmethylclobazam, are partial benzodiazepine receptor agonists at cloned GABAA receptors expressed in Xenopus laevis oocytes. Neurology 78:85","journal-title":"Neurology"},{"key":"4181_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1124\/pr.108.00505","volume":"60","author":"RW Olsen","year":"2008","unstructured":"Olsen RW, Sieghart W (2008) International Union of Pharmacology. LXX. Subtypes of \u03b3-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function. Update Pharmacol Rev 60:243\u2013260. https:\/\/doi.org\/10.1124\/pr.108.00505","journal-title":"Update Pharmacol Rev"},{"key":"4181_CR25","doi-asserted-by":"publisher","first-page":"e88456","DOI":"10.1371\/journal.pone.0088456","volume":"9","author":"HS Jensen","year":"2014","unstructured":"Jensen HS, Nichol K, Lee D, Ebert B (2014) Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for \u03b12-versus \u03b11-GABAA-receptor complexes. PLoS ONE 9:e88456. https:\/\/doi.org\/10.1371\/journal.pone.0088456","journal-title":"PLoS ONE"},{"key":"4181_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","volume":"118","author":"J Riss","year":"2008","unstructured":"Riss J, Cloyd J, Gates J, Collins S (2008) Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 118:69\u201386. https:\/\/doi.org\/10.1111\/j.1600-0404.2008.01004.x","journal-title":"Acta Neurol Scand"},{"key":"4181_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.neuint.2018.05.015","volume":"118","author":"MC Gravielle","year":"2018","unstructured":"Gravielle MC (2018) Regulation of GABAA receptors by prolonged exposure to endogenous and exogenous ligands. Neurochem Int 118:96\u2013104","journal-title":"Neurochem Int"},{"key":"4181_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4274\/tnd.2019.22755","volume":"26","author":"D \u00c7etinkaya","year":"2020","unstructured":"\u00c7etinkaya D, Yeni SN (2020) The use of clobazam as add-on treatment in resistant epilepsy: our retrospective clinical data. Turk J Neurol 26:10\u201313","journal-title":"Turk J Neurol"},{"key":"4181_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1600-0404.1996.tb00180.x","volume":"93","author":"G Barcs","year":"1996","unstructured":"Barcs G, Halasz P (1996) Effectiveness and tolerance of clobazam in temporal lobe epilepsy. Acta Neurol Scand 93:88\u201393. https:\/\/doi.org\/10.1111\/j.1600-0404.1996.tb00180.x","journal-title":"Acta Neurol Scand"},{"key":"4181_CR30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/jnnp.47.12.1279","volume":"47","author":"M Feely","year":"1984","unstructured":"Feely M, Gibson J (1984) Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry 47:1279\u20131282. https:\/\/doi.org\/10.1136\/jnnp.47.12.1279","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4181_CR31","doi-asserted-by":"publisher","first-page":"CD013225","DOI":"10.1002\/14651858.CD013225.pub3","volume":"9","author":"MJ Maguire","year":"2021","unstructured":"Maguire MJ, Nevitt SJ (2021) Treatments for seizures in catamenial (menstrual-related) epilepsy. Cochrane Database Syst Rev 9:CD013225. https:\/\/doi.org\/10.1002\/14651858.CD013225.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"4181_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","volume":"52","author":"W L\u00f6scher","year":"2011","unstructured":"L\u00f6scher W, Schmidt D (2011) Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52:657\u2013678. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03024.x","journal-title":"Epilepsia"},{"key":"4181_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcph.1313","volume":"59","author":"D Tolbert","year":"2019","unstructured":"Tolbert D, Larsen F (2019) A comprehensive overview of the clinical pharmacokinetics of clobazam. J Clin Pharmacol 59:7\u201319. https:\/\/doi.org\/10.1002\/jcph.1313","journal-title":"J Clin Pharmacol"},{"key":"4181_CR34","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2147\/TCRM.S55930","volume":"11","author":"MA Faulkner","year":"2015","unstructured":"Faulkner MA (2015) Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome. Ther Clin Risk Manag 11:905\u2013914. https:\/\/doi.org\/10.2147\/TCRM.S55930","journal-title":"Ther Clin Risk Manag"},{"key":"4181_CR35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3390\/pharmaceutics17070813","volume":"17","author":"Y Tuo","year":"2025","unstructured":"Tuo Y, Yu X, Li S, Wang J, Liu M, Song X et al (2025) Population pharmacokinetics and model-informed precision dosing of clobazam based on the developmental and genetic characteristics of children with epilepsy. Pharmaceutics 17:813. https:\/\/doi.org\/10.3390\/pharmaceutics17070813","journal-title":"Pharmaceutics"},{"key":"4181_CR36","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1684\/epd.2022.1492","volume":"24","author":"T Tomson","year":"2022","unstructured":"Tomson T, Battino D, Bromley R, Kochen S, Meador KJ, Pennell PB et al (2022) Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force. Epileptic Disord 24:1020\u20131032. https:\/\/doi.org\/10.1684\/epd.2022.1492","journal-title":"Epileptic Disord"},{"key":"4181_CR37","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","volume":"32","author":"C Giraud","year":"2004","unstructured":"Giraud C, Tran A, Rey E, Vincent J, Tr\u00e9luyer JM, Pons G (2004) In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 32:1279\u20131286. https:\/\/doi.org\/10.1124\/dmd.32.11.1279","journal-title":"Drug Metab Dispos"},{"key":"4181_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.80.7_supplement.P01.042","volume":"80","author":"D Tolbert","year":"2013","unstructured":"Tolbert D, Bekersky I (2013) Pharmacokinetics of N-desmethylclobazam, the active and primary metabolite of clobazam. Neurology 80:1\u20134","journal-title":"Neurology"},{"key":"4181_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00228-014-1773-z","volume":"71","author":"S Hashi","year":"2015","unstructured":"Hashi S, Yano I, Shibata M, Masuda S, Kinoshita M, Matsumoto R et al (2015) Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. Eur J Clin Pharmacol 71:51\u201358. https:\/\/doi.org\/10.1007\/s00228-014-1773-z","journal-title":"Eur J Clin Pharmacol"},{"key":"4181_CR40","doi-asserted-by":"publisher","first-page":"857","DOI":"10.5124\/jkma.25.0128","volume":"68","author":"BW Yoo","year":"2025","unstructured":"Yoo BW (2025) Comprehension and practical considerations in pediatric pharmacotherapy: a narrative review. J Korean Med Assoc 68:857\u2013867. https:\/\/doi.org\/10.5124\/jkma.25.0128","journal-title":"J Korean Med Assoc"},{"key":"4181_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","volume":"35","author":"J de Leon","year":"2013","unstructured":"de Leon J, Spina E, Diaz FJ (2013) Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit 35:30\u201347. https:\/\/doi.org\/10.1097\/FTD.0b013e31827ada88","journal-title":"Ther Drug Monit"},{"key":"4181_CR42","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/jpm15110549","volume":"15","author":"B Eltanameli","year":"2025","unstructured":"Eltanameli B, Al Sahlawi S, Cristofoletti R (2025) Physiologically based pharmacokinetic modeling of clobazam and stiripentol co-therapy in dravet syndrome. J Pers Med 15:549. https:\/\/doi.org\/10.3390\/jpm15110549","journal-title":"J Pers Med"},{"key":"4181_CR43","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.6039\/j.issn.1001-0408.2024.15.16","volume":"35","author":"C Tu","year":"2024","unstructured":"Tu C, Ren D, Shen J, Li Y, Yang Y, Yan A et al (2024) Efficacy and safety of clobazam in the additional treatment of refractory epilepsy in children: meta-analysis of single-group rate. China Pharm 35:1893\u20131898. https:\/\/doi.org\/10.6039\/j.issn.1001-0408.2024.15.16","journal-title":"China Pharm"},{"key":"4181_CR44","doi-asserted-by":"publisher","first-page":"10899","DOI":"10.2147\/DDDT.S560731","volume":"19","author":"L Yu","year":"2025","unstructured":"Yu L, Chen S, Zhang Z, Hu Y, Fang Y, Mao F et al (2025) Efficacy and safety of clobazam adjunctive therapy in pediatric patients with drug-resistant epilepsy. Drug Des Devel Ther 19:10899\u201310908. https:\/\/doi.org\/10.2147\/DDDT.S560731","journal-title":"Drug Des Devel Ther"},{"key":"4181_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jns.2007.05.025","volume":"263","author":"M Kinoshita","year":"2007","unstructured":"Kinoshita M, Ikeda A, Begum T, Terada K, Shibasaki H (2007) Efficacy of low-dose, add-on therapy of clobazam (CLB) is produced by its major metabolite, N-desmethyl-CLB. J Neurol Sci 263:44\u201348","journal-title":"J Neurol Sci"},{"key":"4181_CR46","doi-asserted-by":"publisher","first-page":"110751","DOI":"10.1016\/j.yebeh.2025.110751","volume":"173","author":"P Satishchandra","year":"2025","unstructured":"Satishchandra P, Rathore C, Kumar A, Apte A, Mandal A, Menon B et al (2025) Effectiveness and safety of clobazam as add-on therapy in children after the failure of first antiseizure medicine: a sub-analysis of the ADD-ON study. Epilepsy Behav 173:110751. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110751","journal-title":"Epilepsy Behav"},{"key":"4181_CR47","doi-asserted-by":"publisher","first-page":"276","DOI":"10.17749\/2077-8333\/epi.par.con.2022.124","volume":"14","author":"E Belousova","year":"2022","unstructured":"Belousova E, Burd S, Ermolenko N, Mukhin KY (2022) Diagnostics and age-related evolution of Lennox-Gastaut syndrome. Management in diverse patient age periods. Epilepsy Paroxysmal Cond 14:276\u2013293. https:\/\/doi.org\/10.17749\/2077-8333\/epi.par.con.2022.124","journal-title":"Epilepsy Paroxysmal Cond"},{"key":"4181_CR48","first-page":"1110","volume":"48","author":"X Tang","year":"2015","unstructured":"Tang X, Xiang S, Xiao N (2015) Clobazam as adjunctive therapy for Lennox-Gastaut syndrome. Chin J Neurol 48:1110\u20131112","journal-title":"Chin J Neurol"},{"key":"4181_CR49","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1212\/wnl.0b013e318232de76","volume":"77","author":"Y Ng","year":"2011","unstructured":"Ng Y, Conry J, Drummond R, Stolle J, Weinberg M (2011) Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 77:1473\u20131481. https:\/\/doi.org\/10.1212\/wnl.0b013e318232de76","journal-title":"Neurology"},{"key":"4181_CR50","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.yebeh.2012.09.039","volume":"25","author":"YT Ng","year":"2012","unstructured":"Ng YT, Conry J, Paolicchi J, Kernitsky L, Mitchell W, Drummond R et al (2012) Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav 25:687\u2013694. https:\/\/doi.org\/10.1016\/j.yebeh.2012.09.039","journal-title":"Epilepsy Behav"},{"key":"4181_CR51","doi-asserted-by":"publisher","first-page":"1522543","DOI":"10.3389\/fphar.2025.1522543","volume":"16","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Zhang Z, Xiao W, Wang C, Liang R (2025) Efficacy and safety of pharmacological and non-pharmacological therapies in Lennox-Gastaut syndrome: a systematic review and network meta-analysis. Front Pharmacol 16:1522543. https:\/\/doi.org\/10.3389\/fphar.2025.1522543","journal-title":"Front Pharmacol"},{"key":"4181_CR52","doi-asserted-by":"publisher","first-page":"1634718","DOI":"10.3389\/fnins.2025.1634718","volume":"19","author":"G Zhang","year":"2025","unstructured":"Zhang G, Huang S, Wei M, Wu Y, Xie Z, Wang J (2025) Dravet syndrome: novel insights into SCN1A-mediated epileptic neurodevelopmental disorders within the molecular diagnostic-therapeutic framework. Front Neurosci 19:1634718. https:\/\/doi.org\/10.3389\/fnins.2025.1634718","journal-title":"Front Neurosci"},{"key":"4181_CR53","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/epi4.12413","volume":"5","author":"K Heger","year":"2020","unstructured":"Heger K, Lund C, Larsen Burns M, S\u00e6tre M, S\u00e6tre E, Johannessen SI et al (2020) A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway. Epilepsia Open 5:432\u2013441. https:\/\/doi.org\/10.1002\/epi4.12413","journal-title":"Epilepsia Open"},{"key":"4181_CR54","volume-title":"Epilepsies: diagnosis and management. NICE Clinical Guideline No. 137","author":"National Institute for Health and Care Excellence","year":"2012","unstructured":"National Institute for Health and Care Excellence (2012) Epilepsies: diagnosis and management. NICE Clinical Guideline No. 137. NICE, London"},{"key":"4181_CR55","doi-asserted-by":"publisher","first-page":"110171","DOI":"10.1016\/j.yebeh.2024.110171","volume":"162","author":"D Samanta","year":"2025","unstructured":"Samanta D (2025) A comprehensive review of evolving treatment strategies for Dravet syndrome: insights from randomized trials, meta-analyses, real-world evidence, and emerging therapeutic approaches. Epilepsy Behav 162:110171. https:\/\/doi.org\/10.1016\/j.yebeh.2024.110171","journal-title":"Epilepsy Behav"},{"key":"4181_CR56","volume-title":"Epilepsies in children, young people and adults. NICE Guideline No. 217","author":"National Institute for Health and Care Excellence","year":"2022","unstructured":"National Institute for Health and Care Excellence (2022) Epilepsies in children, young people and adults. NICE Guideline No. 217. NICE, London"},{"key":"4181_CR57","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/FTD.0000000000000676","volume":"42","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto Y, Takahashi Y, Ikeda H, Imai K, Kagawa Y, Inoue Y (2020) Impact of CYP2C19 phenotypes on clinical efficacy of stiripentol in Japanese patients with Dravet syndrome. Ther Drug Monit 42:302\u2013308. https:\/\/doi.org\/10.1097\/FTD.0000000000000676","journal-title":"Ther Drug Monit"},{"key":"4181_CR58","volume-title":"Clobazam tablet [prescribing information]","author":"Zydus Pharmaceuticals (USA) Inc","year":"2025","unstructured":"Zydus Pharmaceuticals (USA) Inc (2025) Clobazam tablet [prescribing information]. Zydus Pharmaceuticals (USA) Inc, Pennington, NJ. https:\/\/dailymed.nlm.nih.gov\/dailymed\/medguide.cfm?setid=53121764-eef6-4ddf-bc46-a2f4265b1888"},{"key":"4181_CR59","unstructured":"Nickels K, Wirrell E (2016) Epilepsy with myoclonic-atonic seizures (Doose syndrome). In: Pellock JM, Nordli DR Jr, Sankar R, Wheless JW (eds) Pellock\u2019s pediatric epilepsy: diagnosis and therapy, 4th edn. Demos Medical Publishing, New York, p 327."},{"key":"4181_CR60","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pediatrneurol.2012.12.022","volume":"48","author":"RH Caraballo","year":"2013","unstructured":"Caraballo RH, Chamorro N, Darra F, Fortini S, Arroyo H (2013) Epilepsy with myoclonic atonic seizures: an electroclinical study of 69 patients. Pediatr Neurol 48:355\u2013362. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2012.12.022","journal-title":"Pediatr Neurol"},{"key":"4181_CR61","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/epi.16752","volume":"62","author":"K Nickels","year":"2021","unstructured":"Nickels K, Kossoff EH, Eschbach K, Joshi C (2021) Epilepsy with myoclonic-atonic seizures (Doose syndrome): clarification of diagnosis and treatment options through a large retrospective multicenter cohort. Epilepsia 62:120\u2013127. https:\/\/doi.org\/10.1111\/epi.16752","journal-title":"Epilepsia"},{"key":"4181_CR62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s13760-021-01606-4","volume":"122","author":"D T\u00fcrkdo\u011fan","year":"2022","unstructured":"T\u00fcrkdo\u011fan D, \u00d6zt\u00fcrk G (2022) CLB add-on treatment in patients with epileptic encephalopathy: a single center experience with long-term follow-up. Acta Neurol Belg 122:51\u201357. https:\/\/doi.org\/10.1007\/s13760-021-01606-4","journal-title":"Acta Neurol Belg"},{"key":"4181_CR63","doi-asserted-by":"publisher","first-page":"106963","DOI":"10.1016\/j.eplepsyres.2022.106963","volume":"184","author":"T Kama\u015fak","year":"2022","unstructured":"Kama\u015fak T, Serdaro\u011flu E, Y\u0131lmaz \u00d6, K\u0131l\u0131\u00e7 BA, Polat BG, Erdo\u011fan I et al (2022) The effectiveness and tolerability of clobazam in the pediatric population: adjunctive therapy and monotherapy in a large-cohort multicenter study. Epilepsy Res 184:106963. https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106963","journal-title":"Epilepsy Res"},{"key":"4181_CR64","doi-asserted-by":"publisher","first-page":"236","DOI":"10.14744\/SEMB.2020.60252","volume":"54","author":"TA Uzunhan","year":"2020","unstructured":"Uzunhan TA, Gor Z (2020) Efficacy and side effect profile of clobazam in children with different etiologies of epilepsy from a single center. Med Bull Sisli Etfal Hosp 54:236\u2013244. https:\/\/doi.org\/10.14744\/SEMB.2020.60252","journal-title":"Med Bull Sisli Etfal Hosp"},{"key":"4181_CR65","doi-asserted-by":"publisher","first-page":"106182","DOI":"10.1016\/j.eplepsyres.2019.106182","volume":"157","author":"D Tolbert","year":"2019","unstructured":"Tolbert D, Chu HM, Ette EI (2019) Pharmacometrics of clobazam in pediatrics: prediction of effective clobazam doses for Dravet syndrome. Epilepsy Res 157:106182. https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106182","journal-title":"Epilepsy Res"},{"key":"4181_CR66","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/FTD.0000000000000277","volume":"38","author":"ML Burns","year":"2016","unstructured":"Burns ML, Baftiu A, Opdal MS, Johannessen SI, Landmark CJ (2016) Therapeutic drug monitoring of clobazam and its metabolite\u2014impact of age and comedication on pharmacokinetic variability. Ther Drug Monit 38:350\u2013357. https:\/\/doi.org\/10.1097\/FTD.0000000000000277","journal-title":"Ther Drug Monit"},{"key":"4181_CR67","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.seizure.2020.11.017","volume":"85","author":"C Joshi","year":"2021","unstructured":"Joshi C, Nickels K, Demarest S, Eltze C, Cross JH, Wirrell E (2021) Results of an international Delphi consensus in epilepsy with myoclonic atonic seizures\/Doose syndrome. Seizure 85:12\u201318. https:\/\/doi.org\/10.1016\/j.seizure.2020.11.017","journal-title":"Seizure"},{"key":"4181_CR68","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/dmcn.15072","volume":"64","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang J, Wang C (2022) Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis. Dev Med Child Neurol 64:305\u2013313. https:\/\/doi.org\/10.1111\/dmcn.15072","journal-title":"Dev Med Child Neurol"},{"key":"4181_CR69","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/S1388-2457(00)00408-9","volume":"111","author":"CA Tassinari","year":"2000","unstructured":"Tassinari CA, Rubboli G, Volpi L, Meletti S, d\u2019Orsi G, Franca M et al (2000) Encephalopathy with electrical status epilepticus during slow sleep or ESES syndrome including the acquired aphasia. Clin Neurophysiol 111:S94\u2013S102. https:\/\/doi.org\/10.1016\/S1388-2457(00)00408-9","journal-title":"Clin Neurophysiol"},{"key":"4181_CR70","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1474-4422(23)00409-X","volume":"23","author":"MM van Arnhem","year":"2024","unstructured":"van Arnhem MM, van den Munckhof B, Arzimanoglou A, Perucca E, Mets\u00e4honkala L, Rubboli G et al (2024) Corticosteroids versus clobazam for treatment of children with epileptic encephalopathy with spike-wave activation in sleep (RESCUE ESES): a multicentre randomised controlled trial. Lancet Neurol 23:147\u2013156. https:\/\/doi.org\/10.1016\/S1474-4422(23)00409-X","journal-title":"Lancet Neurol"},{"key":"4181_CR71","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/epi.18680","volume":"67","author":"MM van Arnhem","year":"2026","unstructured":"van Arnhem MM, Vijn LJ, Rubboli G, Khinchi MS, Dimova P, Perucca E et al (2026) Clobazam versus corticosteroid for developmental and epileptic encephalopathy with spike\u2013wave activation in sleep ((D)EE-SWAS): results of a multicenter observational study. Epilepsia 67:634\u2013645. https:\/\/doi.org\/10.1111\/epi.18680","journal-title":"Epilepsia"},{"key":"4181_CR72","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/phar.1855","volume":"36","author":"MSA Campos","year":"2016","unstructured":"Campos MSA, Ayres LR, Morelo MRS, Marques FA, Pereira LRL (2016) Efficacy and tolerability of antiepileptic drugs in patients with focal epilepsy: systematic review and network meta-analyses. Pharmacotherapy 36:1255\u20131271. https:\/\/doi.org\/10.1002\/phar.1855","journal-title":"Pharmacotherapy"},{"key":"4181_CR73","unstructured":"Merck Sharp & Dohme Corp (2026) Medications used to treat seizures. In: MSD Manuals. Merck & Co., Inc. https:\/\/www.msdmanuals.com\/home\/multimedia\/table\/medications-used-to-treat-seizures"},{"key":"4181_CR74","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.yebeh.2019.03.040","volume":"95","author":"J Hahn","year":"2019","unstructured":"Hahn J, Lee H, Kang HC, Lee JS, Kim HD, Kim SH et al (2019) Clobazam as an adjunctive treatment for infantile spasms. Epilepsy Behav 95:161\u2013165. https:\/\/doi.org\/10.1016\/j.yebeh.2019.03.040","journal-title":"Epilepsy Behav"},{"key":"4181_CR75","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1055\/s-0040-1708562","volume":"6","author":"M Iype","year":"2020","unstructured":"Iype M, Koshy KG (2020) Management of infantile spasms: an updated review. Int J Epilepsy 6:4\u201314. https:\/\/doi.org\/10.1055\/s-0040-1708562","journal-title":"Int J Epilepsy"},{"key":"4181_CR76","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.18203\/2349-3291.ijcp20190720","volume":"6","author":"V Kumar","year":"2019","unstructured":"Kumar V, Gupta A (2019) Intermittent clobazam prophylaxis in simple febrile convulsions: a randomised controlled trial. Int J Contemp Pediatr 6:1104\u20131109. https:\/\/doi.org\/10.18203\/2349-3291.ijcp20190720","journal-title":"Int J Contemp Pediatr"},{"key":"4181_CR77","doi-asserted-by":"publisher","first-page":"740","DOI":"10.36348\/sjmps.2025.v11i08.002","volume":"11","author":"AM Algarni","year":"2025","unstructured":"Algarni AM, Alazmi AA (2025) Systematic review of updates on pharmacological management of recurrent febrile convulsions. Saudi J Med Pharm Sci 11:740\u2013746. https:\/\/doi.org\/10.36348\/sjmps.2025.v11i08.002","journal-title":"Saudi J Med Pharm Sci"},{"key":"4181_CR78","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.seizure.2016.01.006","volume":"35","author":"J Lotte","year":"2016","unstructured":"Lotte J, Bast T, Borusiak P, Coppola A, Cross JH, Dimova P et al (2016) Effectiveness of antiepileptic therapy in patients with PCDH19 mutations. Seizure 35:106\u2013110. https:\/\/doi.org\/10.1016\/j.seizure.2016.01.006","journal-title":"Seizure"},{"key":"4181_CR79","doi-asserted-by":"publisher","unstructured":"Specchio N, Pietrafusa N, Perucca E, Cross JH (2022) New paradigms for the treatment of pediatric monogenic epilepsies: progressing toward precision medicine. Epilepsy Behav 131(Pt B):107961. https:\/\/doi.org\/10.1016\/j.yebeh.2021.107961","DOI":"10.1016\/j.yebeh.2021.107961"},{"key":"4181_CR80","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1756285614521314","volume":"7","author":"G Purcarin","year":"2014","unstructured":"Purcarin G, Ng YT (2014) Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome. Ther Adv Neurol Disord 7:169\u2013176. https:\/\/doi.org\/10.1177\/1756285614521314","journal-title":"Ther Adv Neurol Disord"},{"key":"4181_CR81","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/14740338.2023.2204227","volume":"23","author":"P An","year":"2024","unstructured":"An P, Liu X, Zhang B (2024) Safety profile of clobazam in the real world: an analysis of FAERS database and systematic review of case reports. Expert Opin Drug Saf 23:119\u2013128. https:\/\/doi.org\/10.1080\/14740338.2023.2204227","journal-title":"Expert Opin Drug Saf"},{"key":"4181_CR82","doi-asserted-by":"publisher","unstructured":"Xie J, Xiang QM, Jia QY, Liu LM (2025) Safety evaluation of rufinamide, clobazam and cannabidiol in the treatment of epilepsy in children. J Pediatr Pharm 31(5). https:\/\/doi.org\/10.13407\/j.cnki.jpp.1672-108X.2025.05.009","DOI":"10.13407\/j.cnki.jpp.1672-108X.2025.05.009"},{"key":"4181_CR83","doi-asserted-by":"publisher","unstructured":"Dong J, Liu ZL, Chen HL, Wu TY, Hong YT, Chen C (2026) A study on the short-term efficacy and safety of clobazam as an add-on therapy for refractory epilepsy in children. Matern Child Health Care China 41(2). https:\/\/doi.org\/10.19829\/j.zgfybj.issn.1001-4411.2026.02.019","DOI":"10.19829\/j.zgfybj.issn.1001-4411.2026.02.019"},{"key":"4181_CR84","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.seizure.2025.01.002","volume":"125","author":"J Qian","year":"2025","unstructured":"Qian J, Xue X, Ezeja L, Boxx Z, Jackson CW (2025) Post-marketing safety of antiseizure medications: focus on serious adverse effects including drug reaction with eosinophilia and systemic symptoms (DRESS). Seizure 125:37\u201343. https:\/\/doi.org\/10.1016\/j.seizure.2025.01.002","journal-title":"Seizure"},{"key":"4181_CR85","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ane.13690","volume":"146","author":"A Sharma","year":"2022","unstructured":"Sharma A, Kumar A (2022) Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis. Acta Neurol Scand 146:623\u2013627. https:\/\/doi.org\/10.1111\/ane.13690","journal-title":"Acta Neurol Scand"},{"key":"4181_CR86","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12991-025-00627-0","volume":"25","author":"JW Figg","year":"2026","unstructured":"Figg JW, Love CA, Sorathia V, Engelbart M, Turner A, Elton A (2026) Benzodiazepines at the crossroads: navigating therapeutic promise and perils of misuse. Ann Gen Psychiatry 25:5. https:\/\/doi.org\/10.1186\/s12991-025-00627-0","journal-title":"Ann Gen Psychiatry"},{"key":"4181_CR87","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/epi.12561","volume":"55","author":"JA Conry","year":"2014","unstructured":"Conry JA, Ng YT, Kernitsky L, Mitchell WG, Veidemanis R, Drummond R et al (2014) Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia 55:558\u2013567. https:\/\/doi.org\/10.1111\/epi.12561","journal-title":"Epilepsia"},{"key":"4181_CR88","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S (2022) Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs 36:1079\u20131111. https:\/\/doi.org\/10.1007\/s40263-022-00955-9","journal-title":"CNS Drugs"},{"key":"4181_CR89","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/epd2.70136","volume":"28","author":"G May\u00e0","year":"2026","unstructured":"May\u00e0 G, Mu\u00f1oz-Lopetegi A, Tercero A, Centeno M, Conde E, Montini A et al (2026) Clinical and EEG characterization of late-onset de novo absence nonconvulsive status epilepticus secondary to benzodiazepine withdrawal. Epileptic Disord 28:68\u201383. https:\/\/doi.org\/10.1002\/epd2.70136","journal-title":"Epileptic Disord"},{"key":"4181_CR90","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.sleep.2024.09.045","volume":"124","author":"C Jambon-Barbara","year":"2024","unstructured":"Jambon-Barbara C, Revol B, Hlavaty A, Joyeux-Faure M, Borel JC, Cracowski JL et al (2024) Signal detection of drugs associated with obstructive and central sleep apnoea. Sleep Med 124:315\u2013322. https:\/\/doi.org\/10.1016\/j.sleep.2024.09.045","journal-title":"Sleep Med"},{"key":"4181_CR91","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/jcph.603","volume":"56","author":"D Tolbert","year":"2016","unstructured":"Tolbert D, Bekersky I, Chu HM, Ette EI (2016) Drug-metabolism mechanism: knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions. J Clin Pharmacol 56:365\u2013374. https:\/\/doi.org\/10.1002\/jcph.603","journal-title":"J Clin Pharmacol"},{"key":"4181_CR92","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ (2018) Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit 40:526\u2013548. https:\/\/doi.org\/10.1097\/FTD.0000000000000546","journal-title":"Ther Drug Monit"},{"key":"4181_CR93","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","volume":"32","author":"M Walzer","year":"2012","unstructured":"Walzer M, Bekersky I, Blum RA, Tolbert D (2012) Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy 32:340\u2013353. https:\/\/doi.org\/10.1002\/j.1875-9114.2012.01028.x","journal-title":"Pharmacotherapy"},{"key":"4181_CR94","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1124\/dmd.105.007237","volume":"34","author":"C Giraud","year":"2006","unstructured":"Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G et al (2006) In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 34:608\u2013611. https:\/\/doi.org\/10.1124\/dmd.105.007237","journal-title":"Drug Metab Dispos"},{"key":"4181_CR95","doi-asserted-by":"publisher","first-page":"1681815","DOI":"10.3389\/fphar.2025.1681815","volume":"16","author":"CE Navarro","year":"2025","unstructured":"Navarro CE (2025) Practical approach to the safe use of cannabidiol in patients with refractory epilepsy: a mini review. Front Pharmacol 16:1681815. https:\/\/doi.org\/10.3389\/fphar.2025.1681815","journal-title":"Front Pharmacol"},{"key":"4181_CR96","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/ane.13351","volume":"143","author":"B Gunning","year":"2021","unstructured":"Gunning B, Mazurkiewicz-Be\u0142dzi\u0144ska M, Chin RF, Bhathal H, Nortvedt C, Dunayevich E et al (2021) Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta Neurol Scand 143:154\u2013163. https:\/\/doi.org\/10.1111\/ane.13351","journal-title":"Acta Neurol Scand"},{"key":"4181_CR97","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5414\/CP203276","volume":"57","author":"B Boyd","year":"2018","unstructured":"Boyd B, Smith S, Gammaitoni A, Galer BS, Farfel GM (2018) A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther 57:11\u201319. https:\/\/doi.org\/10.5414\/CP203276","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4181_CR98","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/ftd.0000000000001146","volume":"46","author":"K Heger","year":"2024","unstructured":"Heger K, Kjeldstadli K, Ring N, Aaberg KM, Kjeldsen SF, Burns ML et al (2024) Pharmacokinetic variability of sulthiame: the impact of age, drug-drug interactions, and biochemical markers of toxicity in patients with epilepsy. Ther Drug Monit 46:237\u2013245. https:\/\/doi.org\/10.1097\/ftd.0000000000001146","journal-title":"Ther Drug Monit"},{"key":"4181_CR99","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/tpj.2015.70","volume":"16","author":"I Fricke-Galindo","year":"2016","unstructured":"Fricke-Galindo I, C\u00e9spedes-Garro C, Rodrigues-Soares F, Naranjo M, Delgado \u00c1, de Andr\u00e9s F et al (2016) Interethnic variation of CYP2C19 alleles, \u2018predicted\u2019 phenotypes and \u2018measured\u2019 metabolic phenotypes across world populations. Pharmacogenomics J 16:113\u2013123. https:\/\/doi.org\/10.1038\/tpj.2015.70","journal-title":"Pharmacogenomics J"},{"key":"4181_CR100","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/FTD.0000000000000530","volume":"40","author":"GR Russell","year":"2018","unstructured":"Russell GR, Phelps SJ, Shelton CM, Wheless JW (2018) Impact of drug interactions on clobazam and N-desmethylclobazam concentrations in pediatric patients with epilepsy. Ther Drug Monit 40:452\u2013462. https:\/\/doi.org\/10.1097\/FTD.0000000000000530","journal-title":"Ther Drug Monit"},{"key":"4181_CR101","doi-asserted-by":"publisher","first-page":"320","DOI":"10.5863\/1551-6776-25.4.320","volume":"25","author":"KE Hamilton","year":"2020","unstructured":"Hamilton KE, Shelton CM, Wheless J, Phelps SJ (2020) Persistent hypersomnolence following clobazam in a child with epilepsy and undiagnosed CYP2C19 polymorphism. J Pediatr Pharmacol Ther 25:320\u2013327. https:\/\/doi.org\/10.5863\/1551-6776-25.4.320","journal-title":"J Pediatr Pharmacol Ther"},{"key":"4181_CR102","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2515\/therapie\/2010028","volume":"65","author":"D Bentu\u00e9-Ferrer","year":"2010","unstructured":"Bentu\u00e9-Ferrer D, Tribut O, Verdier MC, Debruyne D (2010) Therapeutic drug monitoring of clobazam. Therapie 65:225\u2013231. https:\/\/doi.org\/10.2515\/therapie\/2010028","journal-title":"Therapie"},{"key":"4181_CR103","doi-asserted-by":"publisher","first-page":"9","DOI":"10.13407\/j.cnki.jpp.1672-108X.2025.11.003","volume":"31","author":"T Zhao","year":"2025","unstructured":"Zhao T, Zhang HL, Sun Y, Li HJ, Yu LH (2025) Determination of clobazam concentration in children with epilepsy by ultra-performance liquid chromatography and its clinical application. J Pediatr Pharm 31:9\u201312. https:\/\/doi.org\/10.13407\/j.cnki.jpp.1672-108X.2025.11.003","journal-title":"J Pediatr Pharm"},{"issue":"11","key":"4181_CR104","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1111\/epi.14581","volume":"59","author":"AH Heller","year":"2018","unstructured":"Heller AH, Wargacki S, Jung C, Buan CV, Wyatt DJ, Schobel AM (2018) Pharmacokinetics of clobazam oral soluble film. Epilepsia 59(11):2153\u20132161. https:\/\/doi.org\/10.1111\/epi.14581","journal-title":"Epilepsia"},{"key":"4181_CR105","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/14656566.2023.2215924","volume":"24","author":"FM Besag","year":"2023","unstructured":"Besag FM, Vasey MJ, Chin RF (2023) Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome. Expert Opin Pharmacother 24:1249\u20131268. https:\/\/doi.org\/10.1080\/14656566.2023.2215924","journal-title":"Expert Opin Pharmacother"},{"key":"4181_CR106","doi-asserted-by":"publisher","first-page":"1140679","DOI":"10.3389\/fnins.2023.1140679","volume":"17","author":"I Bertocchi","year":"2023","unstructured":"Bertocchi I, Cambiaghi M, Hasan MT (2023) Advances toward precision therapeutics for developmental and epileptic encephalopathies. Front Neurosci 17:1140679. https:\/\/doi.org\/10.3389\/fnins.2023.1140679","journal-title":"Front Neurosci"},{"key":"4181_CR107","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/FTD.0000000000000015","volume":"36","author":"J Saruwatari","year":"2014","unstructured":"Saruwatari J, Ogusu N, Shimomasuda M, Nakashima H, Seo T, Tanikawa K et al (2014) Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in Japanese patients with epilepsy. Ther Drug Monit 36:302\u2013309","journal-title":"Ther Drug Monit"},{"key":"4181_CR108","doi-asserted-by":"publisher","first-page":"e200151","DOI":"10.1212\/NXI.0000000000200151","volume":"10","author":"PJ Serrano-Castro","year":"2023","unstructured":"Serrano-Castro PJ, Rodr\u00edguez-Uranga JJ, Cabezudo-Garc\u00eda P, Garc\u00eda-Mart\u00edn G, Romero-Godoy J, Estivill-Torr\u00fas G et al (2023) Cenobamate and clobazam combination as personalized medicine in autoimmune-associated epilepsy with anti-Gad65 antibodies. Neurol Neuroimmunol Neuroinflamm 10:e200151. https:\/\/doi.org\/10.1212\/NXI.0000000000200151","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4181_CR109","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/FTD.0b013e318283b49a","volume":"35","author":"Y Yamamoto","year":"2013","unstructured":"Yamamoto Y, Takahashi Y, Imai K, Miyakawa K, Nishimura S, Kasai R et al (2013) Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy. Ther Drug Monit 35:305\u2013312. https:\/\/doi.org\/10.1097\/FTD.0b013e318283b49a","journal-title":"Ther Drug Monit"},{"key":"4181_CR110","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/17512433.2025.2545403","volume":"18","author":"M Giacon","year":"2025","unstructured":"Giacon M, Terrazzino S (2025) Unravelling the genetic complexity of drug-resistant epilepsy: a critical narrative review. Expert Rev Clin Pharmacol 18:503\u2013517. https:\/\/doi.org\/10.1080\/17512433.2025.2545403","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4181_CR111","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2014.01.025","volume":"51","author":"J Klehm","year":"2014","unstructured":"Klehm J, Thome-Souza S, S\u00e1nchez Fern\u00e1ndez I, Bergin AM, Bolton J, Harini C et al (2014) Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. Pediatr Neurol 51:60\u201366. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2014.01.025","journal-title":"Pediatr Neurol"},{"key":"4181_CR112","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.19803\/j.1672-8629.20230226","volume":"20","author":"J Peng","year":"2023","unstructured":"Peng J, Tuo YL, Li QL, Zhou R, Li XL, Peng H (2023) Data analysis of adverse events of clobazam among children based on foreign pharmacovigilance safety spontaneous reporting system. Chin J Pharm Vigil 20:1264\u20131268. https:\/\/doi.org\/10.19803\/j.1672-8629.20230226","journal-title":"Chin J Pharm Vigil"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04181-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04181-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04181-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:47:47Z","timestamp":1789454867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04181-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":112,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4181"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04181-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"30 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"248"}}